AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 31 min read$KMTS

Moran Timothy P. sold $348K of KMTS

Moran Timothy P. (Chief Business Officer) sold 15,256 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $22.83 ($22.61–$23.76, $0.35M total) across 3 trades over 2026-07-30 to 2026-08-03.

Original reporting
SEC EDGAR · Moran Timothy P.
Published Aug 3, 2026, 11:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 11:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The newest information is the disclosed open-market sale amount, share count, and trade window by the CBO. Without additional company-specific catalysts, the trading impact is likely sentiment-driven rather than fundamental.

02

Market read

Traders may monitor for follow-on insider activity, but this single sale alone is unlikely to change valuation absent other news.

03

What to watch

The filing does not state a 10b5-1 plan and includes multiple trade dates and prices, but it provides no reason for the sale or any concurrent corporate event.

Relevance 4/10Novelty 5/10Timing: filed 2026-08-03 after-hours (SEC Form 4)

Background

This is an SEC Form 4 insider transaction disclosure for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS).

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Form 4 shows CBO Timothy P. Moran sold $348,310.62 of KMTS shares in open-market trades from 2026-07-30 to 2026-08-03.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or other disclosures emerge.

Evidence & confidence

The transaction is an open-market sale with no 10b5-1 plan stated, but the article provides no accompanying earnings, guidance, deal, or regulatory catalyst.

Market effects

Sector

No sector-wide signal; this is a single-company insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales are often routine for diversification or tax planning, so the market may discount the signal quickly.

Key entities

  • issuer
    KMTS

    Kestra Medical Technologies, Ltd., the company whose insider transaction is disclosed.

  • insider
    Timothy P. Moran

    Chief Business Officer who sold shares via open-market transactions.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KMTS insider trading history →

Related articles

SEP 16
$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.

tipranks.com3 min
SEP 15
$KMTSMed

Kestra (KMTS) Q1 2027 Earnings Call Transcript

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue of $31.0M, up 60% YoY, and raised full-year guidance to $141M. Gross margin increased to 56.5%, driven by volume leverage and cost improvements. The company invested heavily in R&D and commercial expansion, resulting in a GAAP net loss of $44.1M. Management highlighted market share gains and expanded payer coverage for non-ischemic patients.

aol.com2 min
SEP 15
$KMTSMedAI 8/10

Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60%

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.

yahoo.com3 min
SEP 14
$KMTSHigh

Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results KIRKLAND, Wash., September 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported

SEC EDGAR 8-K2 min